Evaluating the Safety and Immunogenicity of MTBVAC
The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa
Age of 12 through 55 years, on the day of enrollment. [+19]
Weight less than 40 kg [+35]